Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
97 hedge funds and large institutions have $194M invested in Concert Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 36 reducing their positions, and 10 closing their positions.
250% more call options, than puts
Call options by funds: $21K | Put options by funds: $6K
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
4% more funds holding
Funds holding: 93 → 97 (+4)
1.31% more ownership
Funds ownership: 62.61% → 63.92% (+1.3%)
17% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 36
26% less capital invested
Capital invested by funds: $264M → $194M (-$69.8M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$7.53M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.04M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.54M |
| 4 |
AIC
AWM Investment Company
New York
|
+$1.44M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.01M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.43M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.42M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$1.85M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.51M |
CNCE Hedge Fund Activity: Q1 2016 in Review
97 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q1 2016, worth a combined $194M — down 26% from $264M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CNCE positions and 10 closed out — a net gain of 4 holders — while 30 added to existing stakes and 36 trimmed.
The largest buyer was BVF Inc, adding an estimated $7.53M. The largest seller was Millennium Management, cutting an estimated $5.01M.
- 97 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q1 2016, up from 93 in Q4 2015.
- Funds reported $194M of Concert Pharmaceuticals, Inc. stock for Q1 2016, down 26% quarter-over-quarter.
- 14 funds opened new Concert Pharmaceuticals, Inc. positions in Q1 2016 and 10 closed out, a net change of +4 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q1 2016 was BVF Inc, an estimated $7.53M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q1 2016 was Millennium Management, an estimated $5.01M sold.
Based on aggregated 13F filings for Q1 2016.